Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy
Pediatric Pulmonology2018Vol. 54(2), pp. 179–185
Citations Over TimeTop 1% of 2018 papers
S. Al-Zaidy, A. Simon Pickard, Kavitha Kotha, Lindsay N. Alfano, Linda Lowes, Grace Paul, Kathleen Church, Kelly J. Lehman, Douglas M. Sproule, Omar Dabbous, B. Maru, Katherine Berry, W. David Arnold, John T. Kissel, Jerry R. Mendell, Richard Shell
Abstract
ClinicalTrials.gov number, NCT02122952.
Related Papers
- → Valproic acid increases SMN levels in spinal muscular atrophy patient cells(2003)288 cited
- → Spinal Muscular Atrophy Diagnostics(2007)107 cited
- → SMN-Inducing Compounds For The Treatment Of Spinal Muscular Atrophy(2012)34 cited
- → Deletion Analysis of SMN1 Exon 7 Alone May Be Necessary and Sufficient for the Diagnosis of Spinal Muscular Atrophy(2011)3 cited
- → AB140. Ten years experiences of diagnosis spinal muscular atrophy using molecular techniques(2015)